F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma

British Journal of Haematology

Volumn 165, Issue 6, 2014, Pages 793-800

  Gentzler, Ryan D ^a   Evens, Andrew M ^b   Rademaker, Alfred W ^a   Weitner, Bing B ^a   Mittal, Bharat B ^a   Dillehay, Gary L ^a   Petrich, Adam M ^a   Altman, Jessica K ^a   Frankfurt, Olga ^a   Variakojis, Daina ^a   Singhal, Seema ^a   Mehta, Jayesh ^a   Williams, Stephanie ^c   Kaminer, Lynne ^d   Gordon, Leo I ^a   Winter, Jane N ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c SPECTRUM HEALTH   (United States)

^d NorthShore Medical Group   (United States)

Author keywords

Chemotherapy; Hodgkin lymphoma; Positron emission tomography; Radiotherapy; Stem cell transplant

Indexed keywords

CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYTARABINE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

CHEMOTHERAPY; HODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY; STEM CELL TRANSPLANT;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHATIC IRRADIATION; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901691984     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12824     Document Type: Article

References (32)

1. Barrington, S.F., Qian, W., Somer, E.J., Franceschetto, A., Bagni, B., Brun, E., Almquist, H., Loft, A., Hojgaard, L., Federico, M., Gallamini, A., Smith, P., Johnson, P., Radford, J. & O'Doherty, M.J. (2010) Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 37, 1824-1833.
2. Czyz, J., Dziadziuszko, R., Knopinska-Postuszuy, W., Hellmann, A., Kachel, L., Holowiecki, J., Gozdzik, J., Hansz, J., Avigdor, A., Nagler, A., Osowiecki, M., Walewski, J., Mensah, P., Jurczak, W., Skotnicki, A., Sedzimirska, M., Lange, A., Sawicki, W., Sulek, K., Wach, M., Dmoszynska, A., Kus, A., Robak, T. & Warzocha, K. (2004) Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Annals of Oncology, 15, 1222-1230.
3. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dorken, B., Ludwig, W.D., Koch, P., Hanel, M., Pfreundschuh, M., Wilhelm, M., Trumper, L., Aulitzky, W.E., Bentz, M., Rummel, M., Sezer, O., Muller-Hermelink, H.K., Hasenclever, D. & Loffler, M. (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Journal of Clinical Oncology, 27, 4548-4554.
4. Engert, A., Plutschow, A., Eich, H.T., Lohri, A., Dorken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K.C., Wilhelm, M., Debus, J., Eble, M.J., Sokler, M., Ho, A., Rank, A., Ganser, A., Trumper, L., Bokemeyer, C., Kirchner, H., Schubert, J., Kral, Z., Fuchs, M., Muller-Hermelink, H.K., Muller, R.P. & Diehl, V. (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. New England Journal of Medicine, 363, 640-652.
5. Engert, A., Eichenauer, D., Harris, N., Mauch, P. & Diehl, V. (2011) Chapter 126: Hodgkin Lymphoma. In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology (ed. by V. Devita, T. Lawrence & S. Rosenberg), pp. 1819-1854. Lippincott Williams & Wilkins, a Wolters Kluwer business, Philadelphia, PA.
6. Evens, A.M., Altman, J.K., Mittal, B.B., Hou, N., Rademaker, A., Patton, D., Kaminer, L., Williams, S., Duffey, S., Variakojis, D., Singhal, S., Tallman, M.S., Mehta, J., Winter, J.N. & Gordon, L.I. (2007) Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Annals of Oncology, 18, 679-688.
7. Goodman, K.A., Riedel, E., Serrano, V., Gulati, S., Moskowitz, C.H. & Yahalom, J. (2008) Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. Journal of Clinical Oncology, 26, 5240-5247.
8. Gordon, L.I., Hong, F., Fisher, R.I., Bartlett, N.L., Connors, J.M., Gascoyne, R.D., Wagner, H., Stiff, P.J., Cheson, B.D., Gospodarowicz, M., Advani, R., Kahl, B.S., Friedberg, J.W., Blum, K.A., Habermann, T.M., Tuscano, J.M., Hoppe, R.T. & Horning, S.J. (2013) Randomized phase III trial of ABVD versus stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of Clinical Oncology, 31, 684-691.
9. Gutierrez-Delgado, F., Holmberg, L., Hooper, H., Petersdorf, S., Press, O., Maziarz, R., Maloney, D., Chauncey, T., Appelbaum, F. & Bensinger, W. (2003) Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplantation, 32, 279-285.
10. Horning, S.J., Chao, N.J., Negrin, R.S., Hoppe, R.T., Long, G.D., Hu, W.W., Wong, R.M., Brown, B.W. & Blume, K.G. (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood, 89, 801-813.
11. Hoskin, P.J., Lowry, L., Horwich, A., Jack, A., Mead, B., Hancock, B.W., Smith, P., Qian, W., Patrick, P., Popova, B., Pettitt, A., Cunningham, D., Pettengell, R., Sweetenham, J., Linch, D. & Johnson, P.W. (2009) Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology, 27, 5390-5396.
12. Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S., Kosary, C.L., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Eisner, M.P., Lewis, D.R., Chen, H.S., Feuer, E.J. & Cronin, K.A. (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), vol. 2012. National Cancer Institute, Bethesda, MD.
13. Josting, A., Rudolph, C., Mapara, M., Glossmann, J.P., Sieniawski, M., Sieber, M., Kirchner, H.H., Dorken, B., Hossfeld, D.K., Kisro, J., Metzner, B., Berdel, W.E., Diehl, V. & Engert, A. (2005a) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Annals of Oncology, 16, 116-123.
14. Josting, A., Nogova, L., Franklin, J., Glossmann, J.P., Eich, H.T., Sieber, M., Schober, T., Boettcher, H.D., Schulz, U., Muller, R.P., Diehl, V. & Engert, A. (2005b) Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. Journal of Clinical Oncology, 23, 1522-1529.
15. Keller, S.F., Kelly, J.L., Sensenig, E., Andreozzi, J., Oliva, J., Rich, L., Constine, L., Becker, M., Phillips, G., Liesveld, J., Fisher, R.I., Bernstein, S.H. & Friedberg, J.W. (2012) Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. Biol Blood Marrow Transplant, 18, 640-647.
16. Lavoie, J.C., Connors, J.M., Phillips, G.L., Reece, D.E., Barnett, M.J., Forrest, D.L., Gascoyne, R.D., Hogge, D.E., Nantel, S.H., Shepherd, J.D., Smith, C.A., Song, K.W., Sutherland, H.J., Toze, C.L., Voss, N.J. & Nevill, T.J. (2005) High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood, 106, 1473-1478.
17. Lister, T.A., Crowther, D., Sutcliffe, S.B., Glatstein, E., Canellos, G.P., Young, R.C., Rosenberg, S.A., Coltman, C.A. & Tubiana, M. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. Journal of Clinical Oncology, 7, 1630-1636.
18. Meignan, M., Gallamini, A., Itti, E., Barrington, S., Haioun, C. & Polliack, A. (2012) Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leukaemia & Lymphoma, 53, 1876-1881.
19. Moskowitz, C.H., Nimer, S.D., Zelenetz, A.D., Trippett, T., Hedrick, E.E., Filippa, D.A., Louie, D., Gonzales, M., Walits, J., Coady-Lyons, N., Qin, J., Frank, R., Bertino, J.R., Goy, A., Noy, A., O'Brien, J.P., Straus, D., Portlock, C.S. & Yahalom, J. (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood, 97, 616-623.
20. Moskowitz, A.J., Yahalom, J., Kewalramani, T., Maragulia, J.C., Vanak, J.M., Zelenetz, A.D. & Moskowitz, C.H. (2010a) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood, 116, 4934-4937.
21. Moskowitz, C.H., Yahalom, J., Zelenetz, A.D., Zhang, Z., Filippa, D., Teruya-Feldstein, J., Kewalramani, T., Moskowitz, A.J., Rice, R.D., Maragulia, J., Vanak, J., Trippett, T., Hamlin, P., Horowitz, S., Noy, A., O'Connor, O.A., Portlock, C., Straus, D. & Nimer, S.D. (2010b) High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. British Journal of Haematology, 148, 890-897.
22. Moskowitz, A., Maragulia, J.C., Kumar, A. & Moskowitz, C.H. (2012a) Semi-quantitative evaluation of pre-transplant FDG-PET in relapsed and refractory Hodgkin lymphoma. Blood, 120, 2015.
23. Moskowitz, C.H., Matasar, M.J., Zelenetz, A.D., Nimer, S.D., Gerecitano, J., Hamlin, P., Horwitz, S., Moskowitz, A.J., Noy, A., Palomba, L., Perales, M.A., Portlock, C., Straus, D., Maragulia, J.C., Schoder, H. & Yahalom, J. (2012b) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood, 119, 1665-1670.
24. Popat, U., Hosing, C., Saliba, R.M., Anderlini, P., van Besien, K., Przepiorka, D., Khouri, I.F., Gajewski, J., Claxton, D., Giralt, S., Rodriguez, M., Romaguera, J., Hagemeister, F., Ha, C., Cox, J., Cabanillas, F., Andersson, B.S. & Champlin, R.E. (2004) Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplantation, 33, 1015-1023.
25. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Boissevain, F., Zschaber, R., Muller, P., Kirchner, H., Lohri, A., Decker, S., Koch, B., Hasenclever, D., Goldstone, A.H. & Diehl, V. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 359, 2065-2071.
26. Shahidi, M., Kamangari, N., Ashley, S., Cunningham, D. & Horwich, A. (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiotherapy and Oncology, 78, 1-5.
27. Smith, S.D., Moskowitz, C.H., Dean, R., Pohlman, B., Sobecks, R., Copelan, E., Andresen, S., Bolwell, B., Maragulia, J.C., Vanak, J.M., Sweetenham, J. & Moskowitz, A.J. (2011) Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. British Journal of Haematology, 153, 358-363.
28. Sureda, A., Arranz, R., Iriondo, A., Carreras, E., Lahuerta, J.J., Garcia-Conde, J., Jarque, I., Caballero, M.D., Ferra, C., Lopez, A., Garcia-Larana, J., Cabrera, R., Carrera, D., Ruiz-Romero, M.D., Leon, A., Rifon, J., Diaz-Mediavilla, J., Mataix, R., Morey, M., Moraleda, J.M., Altes, A., Lopez-Guillermo, A., de la Serna, J., Fernandez-Ranada, J.M., Sierra, J. & Conde, E. (2001) Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. Journal of Clinical Oncology, 19, 1395-1404.
29. Sureda, A., Constans, M., Iriondo, A., Arranz, R., Caballero, M.D., Vidal, M.J., Petit, J., Lopez, A., Lahuerta, J.J., Carreras, E., Garcia-Conde, J., Garcia-Larana, J., Cabrera, R., Jarque, I., Carrera, D., Garcia-Ruiz, J.C., Pascual, M.J., Rifon, J., Moraleda, J.M., Perez-Equiza, K., Albo, C., Diaz-Mediavilla, J., Torres, A., Torres, P., Besalduch, J., Marin, J., Mateos, M.V., Fernandez-Ranada, J.M., Sierra, J. & Conde, E. (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Annals of Oncology, 16, 625-633.
30. Sweetenham, J.W., Taghipour, G., Milligan, D., Blystad, A.K., Caballero, D., Fassas, A. & Goldstone, A.H. (1997) High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 20, 745-752.
31. von Tresckow, B., Plutschow, A., Fuchs, M., Klimm, B., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M.S., Meissner, J., Zijlstra, J.M., Soekler, M., Stein, H., Eich, H.T., Mueller, R.P., Diehl, V., Borchmann, P. & Engert, A. (2012) Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology, 30, 907-913.
32. Yahalom, J., Gulati, S.C., Toia, M., Maslak, P., McCarron, E.G., O'Brien, J.P., Portlock, C.S., Straus, D.J., Phillips, J. & Fuks, Z. (1993) Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. Journal of Clinical Oncology, 11, 1062-1070.